Madison Muller is a reporter whose work has been featured in various publications including Bloomberg News, The Keene Sentinel, and Yahoo Finance. With a wide range of topics covered, Madison's articles delve into issues related to healthcare, pharmaceuticals, business, and more.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Madison Muller's articles primarily focus on healthcare and pharmaceuticals, often referencing data and government announcements. She highlights news related to drug trials, pharmaceutical companies, and specific drugs' effects.
To effectively reach out to Madison, consider providing insights from industry experts or professionals with direct experience in the healthcare or pharmaceutical sectors. Given her reliance on data and government announcements, pitches backed by credible sources or studies may be particularly effective in capturing her attention.
It seems that Madison does not have a specific geographic focus but instead covers global developments within the healthcare and pharmaceutical industries. Therefore, when reaching out to her about industry trends or breaking news within these sectors, an international perspective could be valuable for your pitch.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.
By: Madison Muller, Jo Constantz
Hims & Hers and other telehealth providers say employers that balked at pricey brand-name shots are investigating cheaper off-brand alternatives.
Novo Nordisk A/S was cited for quality lapses at a drug production plant in Denmark that’s known for making its hit medicines Ozempic and Wegovy.
Novo Nordisk A/S was cited for quality lapses at a drug production plant in Denmark that makes the hit medicines Ozempic and Wegovy.
Eli Lilly & Co. lowered its full-year guidance Wednesday after sales of its blockbuster weight-loss drug fell short of expectations, which the company blamed on inventory issues.
Eli Lilly & Co. lowered its full-year guidance Wednesday after sales of its blockbuster weight-loss drug fell short of expectations, which the company blamed on inventory issues.
Viking Therapeutics Inc. said higher doses of its experimental pill increased patients’ weight loss beyond earlier formulations, strengthening its case to eventually compete with blockbuster shots from Novo Nordisk A/S and Eli Lilly & Co.
By: Madison Muller, Naomi Kresge
Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than some other next-generation contenders in the growing market for obesity drugs.
Howdy, it’s Madison in San Antonio! I’ve spent the last three days at ObesityWeek talking to investors, analysts and doctors about what’s next in pharma’s hottest market. More on that in a second, but first ...
AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a probe into alleged legal breaches tied to drug importation and data privacy.
(833) 317-6278 
